Poltreg S.A. Logo

Poltreg S.A.

Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.

PTG | WAR

Overview

Corporate Details

ISIN(s):
PLPLTRG00012 (+2 more)
LEI:
259400XSAJTERJ42VZ86
Country:
Poland
Address:
GDAŃSK BOTANICZNA 20, 80-298 GDAŃSK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Poltreg S.A. is a clinical-stage biotechnology company pioneering the development of T-regulatory cell (Treg) therapies for autoimmune diseases. The company aims to establish Tregs as a new class of disease-modifying therapeutics. Its advanced pipeline features several clinical assets, with the lead candidate, PTG-007, being developed for Type-1 Diabetes and Multiple Sclerosis (MS). Poltreg is also advancing engineered cell therapies, including first-in-class CAR-Treg programs for MS and Amyotrophic Lateral Sclerosis (ALS). Leveraging its own manufacturing facilities and extensive experience, the company was the first to administer a Treg-based therapy to a patient.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-19 17:15
Regulatory News Service
Raport kwartalny 3Q 2025
Polish 3.1 MB
2025-11-10 13:17
Regulatory News Service
Przyznanie europejskiego patentu dotyczącego metody ekspansji ex vivo limfocytó…
Polish 818 bytes
2025-11-07 09:11
Board/Management Information
Powołanie do Rady Dyrektorów Immuthera C-corp renomowanego naukowca i lidera br…
Polish 1.7 KB
2025-10-31 13:04
Major Shareholding Notification
Formularz
Polish 789.9 KB
2025-10-31 13:04
Declaration of Voting Results & Voting Rights Announcements
Zawiadomienie od TFI Allianz Polska S.A. o zmianie udziału w ogólnej liczby gło…
Polish 502 bytes
2025-09-10 17:09
Audit Report / Information
Raport biegłego rewidenta z przeglądu sprawozdania finansowego
Polish 233.4 KB
2025-09-10 17:09
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności za okres 6 miesięcy zakończony dnia 30 czer…
Polish 2.8 MB
2025-09-10 17:09
Interim Report
Sprawozdanie finansowe za okres 6 miesięcy zakończony dnia 30 czerwca 2025 roku
Polish 3.4 MB
2025-09-03 10:39
Regulatory News Service
Warunkowe przyznanie patentu przez Koreański Urząd Patentowy w projekcie terapi…
Polish 1.7 KB
2025-08-04 14:37
Legal Proceedings Report
Podanie pierwszemu pacjentowi terapii w ramach badania klinicznego fazy II w pr…
Polish 2.8 KB
2025-07-31 08:50
Legal Proceedings Report
Otrzymanie od FDA protokołu z podsumowaniem spotkania pre-IND - Content (PL)
Polish 2.0 KB
2025-07-29 14:05
Regulatory News Service
Otrzymanie Certyfikatu Dobrej Praktyki Wytwarzania od Głównego Inspektora Farma…
Polish 1005 bytes
2025-06-23 15:30
Regulatory News Service
Warunkowe przyznanie europejskiego patentu dotyczącego metody ekspansji ex vivo…
Polish 884 bytes
2025-06-13 15:56
Foreign Filer Report
Rejestracja spółki zależnej Immuthera w USA - Content (PL)
Polish 784 bytes
2025-05-21 12:30
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Zgromadze…
Polish 2.3 KB

Automate Your Workflow. Get a real-time feed of all Poltreg S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Poltreg S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Poltreg S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.